JUDICIALIZATION OF ACCESS TO ANTINEOPLASIC AGENST IN ONCOLOGY SECTOR AT UFPEL HOSPITAL SCHOOL

Authors

  • Suelen de Mattos Cervi Centro de Ciências Químicas, Farmacêuticas e de Alimentos, Universidade Federal de Pelotas - UFPel
  • Rosiane Mastelari Martins Setor de Oncologia, Hospital Escola da Universidade Federal de Pelotas
  • Roberta Socoowski Britto Centro de Ciências Químicas, Farmacêuticas e de Alimentos, Universidade Federal de Pelotas
  • Paulo Maximiliano Corrêa Centro de Ciências Químicas, Farmacêuticas e de Alimentos, Universidade Federal de Pelotas
  • Claiton Leoneti Lencina Universidade Federal de Pelotas

DOI:

https://doi.org/10.21527/2176-7114.2020.40.215-225

Keywords:

Antineoplastics, judicialization of health, oncology, pharmaceutical assistance

Abstract

Lawsuits regarding oncologic drugs are a growing reality in Brazil, causing great financial impact in the public administration. Due to the high cost associated with these drugs, in addition to the high complexity of the treatment, an insightful technical analysis is necessary to ensure the efficacy of the treatment, as well as the justifiable use of public money. The goal of this work was to analyze the profile of the lawsuit demands answered in the oncology sector of the UFPel School Hospital, along with the financial impact of these lawsuits to the public coffers. From January of 2017 to August of 2019 the oncology sector complied with 146 judicial decisions, with a total cost of nearly R$ 11,439,544.00 to the public coffers. In descending order, the drugs that were judicially demanded more often were: bortezomib, abiraterone, bevacizumab, trastuzumab, rituximab and pazopanib; being multiple myeloma, prostate cancer, colorectal cancer, breast cancer and kidney cancer the most prevalent malignancies. It is made evident that the effects are negative for the public administration as it generates budgetary and financial imbalances. However, this work points towards problems involved in the process, as well as strategies that can possibly be applied in short and long term by federative, judiciary and assistance entities, in order to minimize the negative consequences of the judicialization while ensuring to the citizen all their rights determined by law.

Downloads

Published

2020-11-04

How to Cite

Cervi, S. de M., Martins, R. M., Britto, R. S., Corrêa, P. M., & Lencina, C. L. (2020). JUDICIALIZATION OF ACCESS TO ANTINEOPLASIC AGENST IN ONCOLOGY SECTOR AT UFPEL HOSPITAL SCHOOL. Revista Contexto & Saúde, 20(40), 215–225. https://doi.org/10.21527/2176-7114.2020.40.215-225

Issue

Vol. 20 No. 40 (2020): jul-dez

Section

Ciências Farmacêuticas & Saúde

License

By publishing in Revista Contexto & Saúde, authors agree to the following terms:

The works are licensed under the Creative Commons Atribuição 4.0 Internacional (CC BY 4.0)  license, which allows:

Share — to copy and redistribute the material in any medium or format;

Adapt — to remix, transform, and build upon the material for any purpose, including commercial.

These permissions are irrevocable, provided that the following terms are respected:

Attribution — authors must be properly credited, with a link to the license and indication of any changes made.

No additional restrictions — no legal or technological measures may be applied that restrict the use permitted by the license.

Notes:

The license does not apply to elements in the public domain or covered by legal exceptions.

The license does not grant all rights necessary for specific uses (e.g., image rights, privacy, or moral rights).

The journal is not responsible for opinions expressed in the articles, which are the sole responsibility of the authors. The Editor, with the support of the Editorial Board, reserves the right to suggest or request modifications when necessary.

Only original scientific articles presenting research results of interest that have not been published or simultaneously submitted to another journal with the same objective will be accepted.

Mentions of trademarks or specific products are intended solely for identification purposes, without any promotional association by the authors or the journal.

License Agreement (for articles published from September 2025): Authors retain copyright over their article and grant Revista Contexto & Saúde the right of first publication.